$TEVA Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in TEVA PHARMACEUTICAL INDUSTRIES LTD.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in TEVA PHARMACEUTICAL INDUSTRIES LTD. Get notifications about new insider transactions in TEVA PHARMACEUTICAL INDUSTRIES LTD for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 04 2018 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Option Exercise | M | 0.00 | 2,711 | 0 | 8,133 | |
| Dec 04 2018 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Sell | S | 21.76 | 933 | 20,304 | 8,829 | 9.8 K to 8.8 K (-9.56 %) |
| Dec 04 2018 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Buy | M | 0.00 | 2,711 | 0 | 9,762 | 7.1 K to 9.8 K (+38.45 %) |
| Nov 07 2018 | TEVA | TEVA PHARMACEUTICA ... | McClellan Michael James | EVP, Chief Financia ... | Option Exercise | M | 0.00 | 695 | 0 | 695 | |
| Nov 07 2018 | TEVA | TEVA PHARMACEUTICA ... | McClellan Michael James | EVP, Chief Financia ... | Sell | S | 22.73 | 346 | 7,865 | 11,644 | 12 K to 11.6 K (-2.89 %) |
| Nov 07 2018 | TEVA | TEVA PHARMACEUTICA ... | McClellan Michael James | EVP, Chief Financia ... | Buy | M | 0.00 | 695 | 0 | 11,990 | 11.3 K to 12 K (+6.15 %) |
| Oct 09 2018 | TEVA | TEVA PHARMACEUTICA ... | Griffin Deborah A | Chief Accounting Of ... | Option Exercise | A | 0.00 | 11,764 | 0 | 11,764 | |
| Oct 09 2018 | TEVA | TEVA PHARMACEUTICA ... | Griffin Deborah A | Chief Accounting Of ... | Option Exercise | A | 19.16 | 30,002 | 574,838 | 30,002 | |
| Sep 20 2018 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Option Exercise | M | 0.00 | 1,241 | 0 | 1,241 | |
| Sep 20 2018 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Sell | S | 23.71 | 1,241 | 29,420 | 1,388 | 2.6 K to 1.4 K (-47.20 %) |
| Sep 20 2018 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Buy | M | 0.00 | 1,241 | 0 | 2,629 | 1.4 K to 2.6 K (+89.41 %) |
| Sep 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, Growth Markets ... | Option Exercise | M | 0.00 | 2,638 | 0 | 2,638 | |
| Sep 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, Growth Markets ... | Sell | S | 23.69 | 1,379 | 32,670 | 7,005 | 8.4 K to 7 K (-16.45 %) |
| Sep 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, Growth Markets ... | Buy | M | 0.00 | 2,638 | 0 | 8,384 | 5.7 K to 8.4 K (+45.91 %) |
| Sep 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Griffin Deborah A | Chief Accounting Of ... | Option Exercise | M | 0.00 | 2,376 | 0 | 2,376 | |
| Sep 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Griffin Deborah A | Chief Accounting Of ... | Sell | S | 23.71 | 2,376 | 56,328 | 0 | 2.4 K to 0 (-100.00 %) |
| Sep 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Griffin Deborah A | Chief Accounting Of ... | Buy | M | 0.00 | 2,376 | 0 | 2,376 | 0 to 2.4 K |
| Sep 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Option Exercise | M | 0.00 | 1,445 | 0 | 1,446 | |
| Sep 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Sell | S | 23.71 | 625 | 14,817 | 7,265 | 7.9 K to 7.3 K (-7.92 %) |
| Sep 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Buy | M | 0.00 | 1,445 | 0 | 7,890 | 6.4 K to 7.9 K (+22.42 %) |
| Sep 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Option Exercise | M | 0.00 | 2,488 | 0 | 2,489 | |
| Sep 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Sell | S | 23.69 | 2,488 | 58,943 | 0 | 2.5 K to 0 (-100.00 %) |
| Sep 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Buy | M | 0.00 | 2,488 | 0 | 2,488 | 0 to 2.5 K |
| Sep 11 2018 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Option Exercise | M | 0.00 | 696 | 0 | 1,394 | |
| Sep 11 2018 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Sell | S | 21.25 | 696 | 14,790 | 0 | 696 to 0 (-100.00 %) |
| Sep 11 2018 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Buy | M | 0.00 | 696 | 0 | 696 | 0 to 696 |
| Sep 05 2018 | TEVA | TEVA PHARMACEUTICA ... | LIEBERMAN GERALD M | Director | Option Exercise | M | 0.00 | 2,162 | 0 | 0 | |
| Sep 05 2018 | TEVA | TEVA PHARMACEUTICA ... | LIEBERMAN GERALD M | Director | Buy | M | 0.00 | 2,162 | 0 | 7,562 | 5.4 K to 7.6 K (+40.04 %) |
| Sep 05 2018 | TEVA | TEVA PHARMACEUTICA ... | Halfon Jean Michel | Director | Option Exercise | M | 0.00 | 2,162 | 0 | 0 | |
| Sep 05 2018 | TEVA | TEVA PHARMACEUTICA ... | Halfon Jean Michel | Director | Buy | M | 0.00 | 2,162 | 0 | 2,162 | 0 to 2.2 K |
| Sep 05 2018 | TEVA | TEVA PHARMACEUTICA ... | Elstein Amir | Director | Option Exercise | M | 0.00 | 2,162 | 0 | 0 | |
| Sep 05 2018 | TEVA | TEVA PHARMACEUTICA ... | Elstein Amir | Director | Buy | M | 0.00 | 2,162 | 0 | 1,995,868 | 2 M to 2 M (+0.11 %) |
| Sep 05 2018 | TEVA | TEVA PHARMACEUTICA ... | Crane Rosemary A | Director | Option Exercise | M | 0.00 | 2,162 | 0 | 0 | |
| Sep 05 2018 | TEVA | TEVA PHARMACEUTICA ... | Crane Rosemary A | Director | Buy | M | 0.00 | 2,162 | 0 | 8,012 | 5.9 K to 8 K (+36.96 %) |
| Sep 05 2018 | TEVA | TEVA PHARMACEUTICA ... | BARER SOL J | Director | Option Exercise | M | 0.00 | 2,162 | 0 | 0 | |
| Sep 05 2018 | TEVA | TEVA PHARMACEUTICA ... | BARER SOL J | Director | Buy | M | 0.00 | 2,162 | 0 | 2,162 | 0 to 2.2 K |
| Aug 13 2018 | TEVA | TEVA PHARMACEUTICA ... | Codner Iris Beck | EVP Global Brand&Co ... | Sell | S | 22.70 | 4,165 | 94,541 | 8,290 | 12.5 K to 8.3 K (-33.44 %) |
| Aug 07 2018 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Buy | P | 21.92 | 2,000 | 43,840 | 6,445 | 4.4 K to 6.4 K (+44.99 %) |
| Jun 07 2018 | TEVA | TEVA PHARMACEUTICA ... | Satchi-Fainaro Ronit | Director | Option Exercise | A | 0.00 | 6,041 | 0 | 6,041 | |
| Jun 07 2018 | TEVA | TEVA PHARMACEUTICA ... | BARER SOL J | Director | Option Exercise | A | 0.00 | 17,565 | 0 | 17,565 | |
| Jun 07 2018 | TEVA | TEVA PHARMACEUTICA ... | Crane Rosemary A | Director | Option Exercise | A | 0.00 | 6,041 | 0 | 6,041 | |
| Jun 07 2018 | TEVA | TEVA PHARMACEUTICA ... | Elstein Amir | Director | Option Exercise | A | 0.00 | 6,041 | 0 | 6,041 | |
| Jun 07 2018 | TEVA | TEVA PHARMACEUTICA ... | GOLDBERG MURRAY A | Director | Option Exercise | A | 0.00 | 6,041 | 0 | 6,041 | |
| Jun 07 2018 | TEVA | TEVA PHARMACEUTICA ... | Halfon Jean Michel | Director | Option Exercise | A | 0.00 | 6,041 | 0 | 6,041 | |
| Jun 07 2018 | TEVA | TEVA PHARMACEUTICA ... | LIEBERMAN GERALD M | Director | Option Exercise | A | 0.00 | 6,041 | 0 | 6,041 | |
| Jun 07 2018 | TEVA | TEVA PHARMACEUTICA ... | MIGNONE ROBERTO | Director | Option Exercise | A | 0.00 | 6,041 | 0 | 6,041 | |
| Jun 07 2018 | TEVA | TEVA PHARMACEUTICA ... | Nisen Perry | Director | Option Exercise | A | 0.00 | 6,041 | 0 | 6,041 | |
| Jun 07 2018 | TEVA | TEVA PHARMACEUTICA ... | Peres Nechemia Jacob | Director | Option Exercise | A | 0.00 | 6,041 | 0 | 6,041 | |
| May 11 2018 | TEVA | TEVA PHARMACEUTICA ... | MIGNONE ROBERTO | Director | Buy | P | 19.32 | 250,000 | 4,829,700 | 1,500,000 | 1.3 M to 1.5 M (+20.00 %) |
| May 11 2018 | TEVA | TEVA PHARMACEUTICA ... | MIGNONE ROBERTO | Director | Buy | P | 19.21 | 500,000 | 9,603,150 | 1,250,000 | 750 K to 1.3 M (+66.67 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Option Exercise | M | 0.00 | 2,358 | 0 | 4,717 | |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Sell | S | 18.38 | 2,358 | 43,340 | 2,974 | 5.3 K to 3 K (-44.22 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Buy | M | 0.00 | 2,358 | 0 | 5,332 | 3 K to 5.3 K (+79.29 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Option Exercise | M | 0.00 | 1,179 | 0 | 2,358 | |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Sell | S | 17.88 | 1,179 | 21,078 | 1,388 | 2.6 K to 1.4 K (-45.93 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Buy | M | 0.00 | 1,179 | 0 | 2,567 | 1.4 K to 2.6 K (+84.94 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, Growth Markets ... | Option Exercise | M | 0.00 | 872 | 0 | 1,746 | |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, Growth Markets ... | Sell | S | 17.89 | 457 | 8,177 | 5,746 | 6.2 K to 5.7 K (-7.37 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, Growth Markets ... | Buy | M | 0.00 | 872 | 0 | 6,203 | 5.3 K to 6.2 K (+16.36 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | McClellan Michael James | EVP, Chief Financia ... | Option Exercise | M | 0.00 | 660 | 0 | 1,321 | |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | McClellan Michael James | EVP, Chief Financia ... | Sell | S | 17.88 | 287 | 5,131 | 11,295 | 11.6 K to 11.3 K (-2.48 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | McClellan Michael James | EVP, Chief Financia ... | Buy | M | 0.00 | 660 | 0 | 11,582 | 10.9 K to 11.6 K (+6.04 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Griffin Deborah A | Chief Accounting Of ... | Option Exercise | M | 0.00 | 943 | 0 | 1,887 | |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Griffin Deborah A | Chief Accounting Of ... | Sell | S | 17.88 | 943 | 16,859 | 0 | 943 to 0 (-100.00 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Griffin Deborah A | Chief Accounting Of ... | Buy | M | 0.00 | 943 | 0 | 943 | 0 to 943 |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Option Exercise | M | 0.00 | 265 | 0 | 531 | |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Option Exercise | M | 0.00 | 747 | 0 | 1,495 | |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Sell | S | 17.88 | 91 | 1,627 | 7,051 | 7.1 K to 7.1 K (-1.27 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Sell | S | 17.88 | 257 | 4,595 | 7,142 | 7.4 K to 7.1 K (-3.47 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Buy | M | 0.00 | 265 | 0 | 7,399 | 7.1 K to 7.4 K (+3.71 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Buy | M | 0.00 | 747 | 0 | 7,134 | 6.4 K to 7.1 K (+11.70 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Option Exercise | M | 0.00 | 1,179 | 0 | 2,358 | |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Sell | S | 17.88 | 571 | 10,208 | 4,445 | 5 K to 4.4 K (-11.38 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Buy | M | 0.00 | 1,179 | 0 | 5,016 | 3.8 K to 5 K (+30.73 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Option Exercise | M | 0.00 | 1,297 | 0 | 2,594 | |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Sell | S | 17.89 | 1,297 | 23,206 | 0 | 1.3 K to 0 (-100.00 %) |
| Mar 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Buy | M | 0.00 | 1,297 | 0 | 1,297 | 0 to 1.3 K |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Option Exercise | M | 0.00 | 2,441 | 0 | 2,444 | |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Sell | S | 19.20 | 2,441 | 46,867 | 2,974 | 5.4 K to 3 K (-45.08 %) |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Buy | M | 0.00 | 2,441 | 0 | 5,415 | 3 K to 5.4 K (+82.08 %) |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Option Exercise | M | 0.00 | 738 | 0 | 738 | |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Sell | S | 19.49 | 738 | 14,383 | 1,388 | 2.1 K to 1.4 K (-34.71 %) |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Buy | M | 0.00 | 738 | 0 | 2,126 | 1.4 K to 2.1 K (+53.17 %) |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, Growth Markets ... | Option Exercise | M | 0.00 | 880 | 0 | 883 | |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, Growth Markets ... | Sell | S | 19.50 | 461 | 8,989 | 5,331 | 5.8 K to 5.3 K (-7.96 %) |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | Nazzi Gianfranco | EVP, Growth Markets ... | Buy | M | 0.00 | 880 | 0 | 5,792 | 4.9 K to 5.8 K (+17.92 %) |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | Griffin Deborah A | Chief Accounting Of ... | Option Exercise | M | 0.00 | 952 | 0 | 953 | |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | Griffin Deborah A | Chief Accounting Of ... | Sell | S | 19.49 | 952 | 18,554 | 0 | 952 to 0 (-100.00 %) |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | Griffin Deborah A | Chief Accounting Of ... | Buy | M | 0.00 | 952 | 0 | 952 | 0 to 952 |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Option Exercise | M | 0.00 | 1,190 | 0 | 1,191 | |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Sell | S | 19.49 | 576 | 11,226 | 3,837 | 4.4 K to 3.8 K (-13.05 %) |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Buy | M | 0.00 | 1,190 | 0 | 4,413 | 3.2 K to 4.4 K (+36.92 %) |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Option Exercise | M | 0.00 | 714 | 0 | 715 | |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Sell | S | 19.50 | 714 | 13,922 | 0 | 714 to 0 (-100.00 %) |
| Mar 14 2018 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Buy | M | 0.00 | 714 | 0 | 714 | 0 to 714 |
| Mar 06 2018 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Option Exercise | M | 0.00 | 1,166 | 0 | 3,498 | |
| Mar 06 2018 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Sell | S | 19.38 | 705 | 13,663 | 1,388 | 2.1 K to 1.4 K (-33.68 %) |
| Mar 06 2018 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Payment of Exercise | F | 19.38 | 461 | 8,934 | 2,093 | 2.6 K to 2.1 K (-18.05 %) |
| Mar 06 2018 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Buy | M | 0.00 | 1,166 | 0 | 2,554 | 1.4 K to 2.6 K (+84.01 %) |
| Mar 06 2018 | TEVA | TEVA PHARMACEUTICA ... | McClellan Michael James | EVP, Chief Financia ... | Option Exercise | M | 0.00 | 1,049 | 0 | 3,148 | |
| Mar 06 2018 | TEVA | TEVA PHARMACEUTICA ... | McClellan Michael James | EVP, Chief Financia ... | Payment of Exercise | F | 19.38 | 455 | 8,818 | 10,922 | 11.4 K to 10.9 K (-4.00 %) |
| Mar 06 2018 | TEVA | TEVA PHARMACEUTICA ... | McClellan Michael James | EVP, Chief Financia ... | Buy | M | 0.00 | 1,049 | 0 | 11,377 | 10.3 K to 11.4 K (+10.16 %) |
| Mar 06 2018 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Option Exercise | M | 0.00 | 1,399 | 0 | 4,198 | |
| Mar 06 2018 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Payment of Exercise | F | 19.38 | 677 | 13,120 | 3,223 | 3.9 K to 3.2 K (-17.36 %) |
| Mar 06 2018 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Buy | M | 0.00 | 1,399 | 0 | 3,900 | 2.5 K to 3.9 K (+55.94 %) |
| Mar 06 2018 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Option Exercise | M | 0.00 | 2,098 | 0 | 6,297 | |
| Mar 06 2018 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Sell | S | 19.28 | 1,108 | 21,362 | 0 | 1.1 K to 0 (-100.00 %) |
| Mar 06 2018 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Payment of Exercise | F | 19.28 | 990 | 19,087 | 1,108 | 2.1 K to 1.1 K (-47.19 %) |
| Mar 06 2018 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Buy | M | 0.00 | 2,098 | 0 | 2,098 | 0 to 2.1 K |
| Feb 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Sabag Mark | EVP, Global Human R ... | Sell | S | 20.52 | 3,000 | 61,560 | 41,517 | 44.5 K to 41.5 K (-6.74 %) |
| Feb 20 2018 | TEVA | TEVA PHARMACEUTICA ... | Sabag Mark | EVP, Global Human R ... | Sell | S | 18.45 | 2,050 | 37,823 | 44,517 | 46.6 K to 44.5 K (-4.40 %) |
| Feb 12 2018 | TEVA | TEVA PHARMACEUTICA ... | Codner Iris Beck | EVP Global Brand&Co ... | Option Exercise | A | 0.00 | 34,031 | 0 | 34,031 | |
| Feb 12 2018 | TEVA | TEVA PHARMACEUTICA ... | Codner Iris Beck | EVP Global Brand&Co ... | Option Exercise | A | 18.61 | 86,762 | 1,614,641 | 86,762 | |
| Feb 12 2018 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Option Exercise | A | 0.00 | 37,614 | 0 | 37,614 | |
| Feb 12 2018 | TEVA | TEVA PHARMACEUTICA ... | Stark David Matthew | Exec. VP Chief Lega ... | Option Exercise | A | 18.61 | 95,890 | 1,784,513 | 95,890 | |
| Feb 12 2018 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Option Exercise | A | 0.00 | 48,361 | 0 | 48,361 | |
| Feb 12 2018 | TEVA | TEVA PHARMACEUTICA ... | O'Grady Brendan P. | EVP, North America ... | Option Exercise | A | 18.61 | 123,288 | 2,294,390 | 123,288 | |
| Feb 12 2018 | TEVA | TEVA PHARMACEUTICA ... | McClellan Michael James | EVP, Chief Financia ... | Option Exercise | A | 0.00 | 48,361 | 0 | 48,361 | |
| Feb 12 2018 | TEVA | TEVA PHARMACEUTICA ... | McClellan Michael James | EVP, Chief Financia ... | Option Exercise | A | 18.61 | 123,288 | 2,294,390 | 123,288 | |
| Feb 12 2018 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Option Exercise | A | 0.00 | 48,361 | 0 | 48,361 | |
| Feb 12 2018 | TEVA | TEVA PHARMACEUTICA ... | Fridriksdottir Hafrun | Executive VP, Globa ... | Option Exercise | A | 18.61 | 123,288 | 2,294,390 | 123,288 | |
| Feb 12 2018 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Option Exercise | A | 0.00 | 39,405 | 0 | 39,405 | |
| Feb 12 2018 | TEVA | TEVA PHARMACEUTICA ... | Dethlefs Sven | EVP Global Marketin ... | Option Exercise | A | 18.61 | 100,457 | 1,869,505 | 100,457 | |
| Feb 12 2018 | TEVA | TEVA PHARMACEUTICA ... | de Notaristefani Carlo | Executive VP Global ... | Option Exercise | A | 0.00 | 62,690 | 0 | 62,690 | |
| Feb 12 2018 | TEVA | TEVA PHARMACEUTICA ... | de Notaristefani Carlo | Executive VP Global ... | Option Exercise | A | 18.61 | 159,819 | 2,974,232 | 159,819 | |
| Feb 12 2018 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Option Exercise | A | 0.00 | 39,405 | 0 | 39,405 | |
| Feb 12 2018 | TEVA | TEVA PHARMACEUTICA ... | Daniell Richard | Exec. VP, European ... | Option Exercise | A | 18.61 | 100,457 | 1,869,505 | 100,457 | |
| Jan 23 2018 | TEVA | TEVA PHARMACEUTICA ... | Suesskind Dan S | Director | Option Exercise | H | 25.00 | 19,700 | 492,500 | 0 | |
| Jan 23 2018 | TEVA | TEVA PHARMACEUTICA ... | Suesskind Dan S | Director | Buy | H | 25.00 | 19,700 | 492,500 | 318,836 | 299.1 K to 318.8 K (+6.59 %) |